交易 Neurocrine Biosciences, Inc. - NBIX CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
- 所有權
交易條件
价差 | 0.90 | ||||||||
多头隔夜费
多头隔夜费
前往平台 | -0.026235% | ||||||||
空头隔夜费
空头隔夜费
前往平台 | 0.004012% | ||||||||
隔夜费时间 | 22:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Neurocrine Biosciences Inc ESG Risk Ratings
High Medium Low Negligible
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Dec 1, 2023 | 116.63 | 0.12 | 0.10% | 116.51 | 117.70 | 115.44 |
Nov 30, 2023 | 116.48 | 3.49 | 3.09% | 112.99 | 116.91 | 112.99 |
Nov 29, 2023 | 113.11 | 2.23 | 2.01% | 110.88 | 114.05 | 110.86 |
Nov 28, 2023 | 112.34 | -0.03 | -0.03% | 112.37 | 112.95 | 111.62 |
Nov 27, 2023 | 112.85 | 1.48 | 1.33% | 111.37 | 113.10 | 110.34 |
Nov 24, 2023 | 112.00 | 1.80 | 1.63% | 110.20 | 112.19 | 110.20 |
Nov 22, 2023 | 110.55 | 0.99 | 0.90% | 109.56 | 111.70 | 109.56 |
Nov 21, 2023 | 109.26 | 1.50 | 1.39% | 107.76 | 110.90 | 107.75 |
Nov 20, 2023 | 109.31 | 1.96 | 1.83% | 107.35 | 109.94 | 107.35 |
Nov 17, 2023 | 108.56 | 0.63 | 0.58% | 107.93 | 109.55 | 107.88 |
Nov 16, 2023 | 108.23 | -1.38 | -1.26% | 109.61 | 109.87 | 107.60 |
Nov 15, 2023 | 110.31 | -1.65 | -1.47% | 111.96 | 112.72 | 110.20 |
Nov 14, 2023 | 112.16 | 1.31 | 1.18% | 110.85 | 114.44 | 110.85 |
Nov 13, 2023 | 109.80 | 3.76 | 3.55% | 106.04 | 110.27 | 105.81 |
Nov 10, 2023 | 106.76 | 0.43 | 0.40% | 106.33 | 108.11 | 102.85 |
Nov 9, 2023 | 112.06 | -2.90 | -2.52% | 114.96 | 115.17 | 111.54 |
Nov 8, 2023 | 114.94 | -1.31 | -1.13% | 116.25 | 117.29 | 114.43 |
Nov 7, 2023 | 116.36 | 2.39 | 2.10% | 113.97 | 117.24 | 113.15 |
Nov 6, 2023 | 113.62 | 1.28 | 1.14% | 112.34 | 114.18 | 111.93 |
Nov 3, 2023 | 112.34 | -0.86 | -0.76% | 113.20 | 114.20 | 112.08 |
Neurocrine Biosciences, Inc. Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
Monday, February 5, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 Q4 2023 Neurocrine Biosciences Inc Earnings Release Q4 2023 Neurocrine Biosciences Inc Earnings ReleaseForecast(预报) -上一页 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 1488.7 | 1133.5 | 1045.9 | 788.087 | 451.24 |
收入 | 1488.7 | 1133.5 | 1045.9 | 788.087 | 451.24 |
總營業費用 | 1309.7 | 1031 | 901.3 | 715.804 | 414.345 |
銷售/一般/行政費用,總計 | 751 | 583.3 | 433.3 | 354.062 | 248.932 |
研究與開發 | 463.8 | 328.1 | 275 | 200.042 | 160.524 |
營業收入 | 179 | 102.5 | 144.6 | 72.283 | 36.895 |
利息收入(費用),非經營淨值 | 34.9 | -1.1 | -37.9 | -25.741 | -15.054 |
Gain (Loss) on Sale of Assets | |||||
其他,淨值 | |||||
稅前淨收入 | 213.9 | 101.4 | 106.7 | 46.542 | 21.841 |
稅後淨收入 | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
未計算非常項目前的淨收益 | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
淨收入 | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
普通股股東可獲收益 (不含非經常性項目) | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
普通股股東可獲收益 (含非經常性項目) | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
攤薄淨收入 | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
攤薄後加權平均股 | 98.9 | 97.9 | 97.8 | 95.732 | 95.386 |
扣除特別項目的每股攤薄盈利 | 1.56218 | 0.91522 | 4.16462 | 0.38662 | 0.22132 |
Dividends per Share - Common Stock Primary Issue | |||||
每股正常攤薄盈利 | 2.08583 | 1.86564 | 5.38021 | 1.66815 | 0.22132 |
收入成本,共計 | 23.2 | 14.3 | 10.1 | 7.428 | 4.889 |
毛利 | 1465.5 | 1119.2 | 1035.8 | 780.659 | 446.351 |
異常費用(收入) | 71.7 | 105.3 | 182.9 | 154.272 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 452.7 | 420.4 | 412 | 387.9 | 378.2 |
收入 | 452.7 | 420.4 | 412 | 387.9 | 378.2 |
收入成本,共計 | 11.5 | 8.5 | 7.7 | 6.1 | 4.8 |
毛利 | 441.2 | 411.9 | 404.3 | 381.8 | 373.4 |
總營業費用 | 379.1 | 534.6 | 308.6 | 300.1 | 393.5 |
銷售/一般/行政費用,總計 | 221.8 | 242.7 | 182.9 | 186.3 | 182.8 |
研究與開發 | 145.8 | 139.5 | 118 | 107.7 | 135.9 |
營業收入 | 73.6 | -114.2 | 103.4 | 87.8 | -15.3 |
利息收入(費用),非經營淨值 | 48 | 10.9 | 14.5 | 10.1 | -8 |
稅前淨收入 | 121.6 | -103.3 | 117.9 | 97.9 | -23.3 |
稅後淨收入 | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
未計算非常項目前的淨收益 | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
淨收入 | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
普通股股東可獲收益 (不含非經常性項目) | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
普通股股東可獲收益 (含非經常性項目) | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
攤薄淨收入 | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
攤薄後加權平均股 | 100.2 | 97.1 | 100.7 | 99 | 95.6 |
扣除特別項目的每股攤薄盈利 | 0.95309 | -0.78888 | 0.88381 | 0.69192 | -0.17678 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | 0.95309 | 0.17441 | 0.88381 | 0.69192 | 0.29916 |
異常費用(收入) | 0 | 143.9 | 0 | 0 | 70 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 1453.5 | 972.8 | 1016.2 | 831.034 | 737.777 |
現金和短期投資 | 989.3 | 711.3 | 801 | 670.524 | 650.913 |
現金等價物 | 262.9 | 340.8 | 187.1 | 112.279 | 141.714 |
短期投資 | 726.4 | 370.5 | 613.9 | 558.245 | 509.199 |
其他流動資産,總計 | 79.1 | 45.5 | 30.1 | 16.647 | 18.594 |
總資産 | 2368.7 | 2072.5 | 1734.7 | 1306.04 | 993.151 |
物業/廠房/設備,總計 - 淨額 | 145.6 | 155.8 | 127.4 | 116.278 | 33.869 |
物業/廠房/設備,總計 - 總額 | 211.9 | 207.7 | 169.1 | 149.837 | 62.14 |
累計折舊,總計 | -66.3 | -51.9 | -41.7 | -33.559 | -28.271 |
長期投資 | 401.5 | 624.4 | 265.3 | 355.522 | 216.028 |
其他長期資産,總計 | 330.9 | 319.5 | 325.8 | 3.206 | 5.477 |
流動負債總額 | 537.7 | 245.8 | 186.5 | 565.287 | 88.233 |
應付賬款 | 46.214 | 38.381 | |||
預提費用 | 129.3 | 99.5 | 81.4 | 72.719 | 34.41 |
應付票據/短期債務 | 0 | 0 | 0 | 408.807 | 0 |
其他流動負債,總計 | 3.3 | 3.5 | 7.5 | 37.547 | 15.442 |
負債總額 | 660.9 | 698.5 | 608.5 | 669.117 | 512.386 |
長期債務總額 | 0 | 335.1 | 317.9 | 0 | 388.496 |
其他負債,總計 | 123.2 | 117.6 | 104.1 | 103.83 | 35.657 |
總權益 | 1707.8 | 1374 | 1126.2 | 636.923 | 480.765 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
普通股 | 0.1 | 0.1 | 0.1 | 0.092 | 0.091 |
額外實收資本 | 2122.4 | 2011.4 | 1849.7 | 1768.12 | 1660.36 |
留存收益(累計赤字) | -406.8 | -635.8 | -725.4 | -1132.7 | -1177.76 |
其他權益,總計 | -7.9 | -1.7 | 1.8 | 1.413 | -1.932 |
總負債和股東權益 | 2368.7 | 2072.5 | 1734.7 | 1306.04 | 993.151 |
已發行普通股總數 | 96.5 | 94.9 | 93.5 | 92.272 | 90.797 |
應收賬款總額,淨額 | 350 | 185.5 | 157.1 | 126.575 | 57.406 |
應收賬款 - 貿易,淨額 | 350 | 185.5 | 157.1 | 126.575 | 57.406 |
長期債務 | 0 | 335.1 | 317.9 | 0 | 388.496 |
總庫存 | 35.1 | 30.5 | 28 | 17.288 | 10.864 |
Payable/Accrued | 235.7 | 142.8 | 97.6 | ||
無形資産,淨額 | 37.2 | ||||
長期債務的當前部分/資本租賃 | 169.4 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 1649.9 | 1496.6 | 1432.8 | 1453.5 | 1205.5 |
現金和短期投資 | 1095.1 | 976.7 | 894.6 | 989.3 | 799.4 |
現金等價物 | 293.7 | 160.2 | 103.8 | 262.9 | 212.2 |
短期投資 | 801.4 | 816.5 | 790.8 | 726.4 | 587.2 |
應收賬款總額,淨額 | 417.8 | 387.6 | 391.6 | 350 | 301.2 |
應收賬款 - 貿易,淨額 | 417.8 | 387.6 | 391.6 | 350 | 301.2 |
總庫存 | 28.8 | 31.7 | 33.4 | 35.1 | 37 |
其他流動資産,總計 | 108.2 | 100.6 | 113.2 | 79.1 | 67.9 |
總資産 | 2848.2 | 2613.1 | 2359.8 | 2368.7 | 2143.4 |
物業/廠房/設備,總計 - 淨額 | 149.6 | 149.1 | 147.2 | 145.6 | 150.5 |
長期投資 | 587.5 | 515.6 | 380.3 | 401.5 | 457.5 |
其他長期資産,總計 | 426.3 | 414.9 | 362.3 | 330.9 | 329.9 |
流動負債總額 | 691.6 | 582.5 | 374.1 | 537.7 | 485.1 |
Payable/Accrued | 394.9 | 391.6 | 355.7 | 347.6 | 297.8 |
預提費用 | 125.9 | 17.7 | 17.6 | 17.4 | 17.3 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 0.9 | 3.5 | 0.8 | 3.3 | 0.8 |
負債總額 | 846.1 | 760.1 | 675.3 | 660.9 | 598.8 |
長期債務總額 | 0 | 0 | 169.5 | 0 | 0 |
長期債務 | 169.5 | 0 | 0 | ||
其他負債,總計 | 154.5 | 177.6 | 131.7 | 123.2 | 113.7 |
總權益 | 2002.1 | 1853 | 1684.5 | 1707.8 | 1544.6 |
Preferred Stock - Non Redeemable, Net | |||||
普通股 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
額外實收資本 | 2308.5 | 2241.9 | 2170.5 | 2122.4 | 2054.3 |
留存收益(累計赤字) | -304.8 | -387.9 | -483.4 | -406.8 | -495.8 |
其他權益,總計 | -1.7 | -1.1 | -2.7 | -7.9 | -14 |
總負債和股東權益 | 2848.2 | 2613.1 | 2359.8 | 2368.7 | 2143.4 |
已發行普通股總數 | 98.2 | 97.6 | 97.5 | 96.5 | 96.1 |
長期債務的當前部分/資本租賃 | 169.9 | 169.7 | 0 | 169.4 | 169.2 |
無形資産,淨額 | 34.9 | 36.9 | 37.2 | 37.2 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
经营活动产生的现金 | 339.4 | 256.5 | 228.5 | 152.054 | 101.364 |
经营活动产生的现金 | 15.1 | 10.9 | 8.6 | 7.452 | 4.024 |
非现金物品 | 217.6 | 135 | 161.2 | 107.349 | 77.986 |
已付现金利息 | 6.6 | 8.6 | 11.6 | 11.644 | 11.644 |
营运资金的变化 | -67.4 | 16.7 | -37.9 | 0.241 | -1.757 |
投资活动产生的现金 | -177.1 | -130.2 | 4.1 | -211.073 | -242.915 |
资本支出 | -16.5 | -23.4 | -10.9 | -14.748 | -24.812 |
其他投资现金流量项目,总计 | -160.6 | -106.8 | 15 | -196.325 | -218.103 |
融资活动产生的现金 | -234.3 | 27.4 | -157.8 | 27.313 | 29.53 |
股票的发行(报废),净额 | 44.7 | 27.5 | 29.1 | 27.313 | 29.53 |
债务的发行(退还),净额 | -279 | -0.1 | -186.9 | 0 | 0 |
现金净变化 | -73.3 | 153.7 | 74.8 | -31.706 | -112.021 |
Cash Taxes Paid | 14.4 | 5.1 | 15.3 | 0.507 | |
Deferred Taxes | 19.1 | 4.3 | -310.7 | ||
Amortization | 0.5 | ||||
外汇效应 | -1.3 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -76.6 | 154.5 | 65.5 | -3 | 13.9 |
Cash From Operating Activities | -125.2 | 339.4 | 196.4 | 97.6 | -40.5 |
Cash From Operating Activities | 4.1 | 15.1 | 11.2 | 7.2 | 3.3 |
Deferred Taxes | -31.6 | 19.1 | 5.6 | -3.4 | -0.3 |
Non-Cash Items | 35.5 | 217.6 | 180 | 147.1 | 18.3 |
Changes in Working Capital | -57.5 | -67.4 | -65.9 | -50.3 | -75.7 |
Cash From Investing Activities | -42.1 | -177.1 | -61.5 | -0.2 | -31.6 |
Capital Expenditures | -8.5 | -16.5 | -14.7 | -16.4 | -7.6 |
Other Investing Cash Flow Items, Total | -33.6 | -160.6 | -46.8 | 16.2 | -24 |
Cash From Financing Activities | 8.2 | -234.3 | -258.9 | -270.3 | 6.1 |
Issuance (Retirement) of Stock, Net | 8.2 | 44.7 | 20.1 | 8.7 | 6.1 |
Issuance (Retirement) of Debt, Net | -279 | -279 | -279 | 0 | |
Net Change in Cash | -159.1 | -73.3 | -124 | -172.9 | -66 |
Cash Taxes Paid | 0.2 | 14.4 | 4.3 | 3.1 | |
Cash Interest Paid | 6.6 | 4.6 | 4.6 | ||
Amortization | 0.9 | 0.5 | |||
Foreign Exchange Effects | -1.3 |
投資者名稱 | 投資者類型 | 流通股百分比 | 持有股份 | 股份變動 | 持有日期 | 換手率 |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 10.6161 | 10366912 | 220306 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.76 | 9530883 | -26814 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.0516 | 3956499 | 156584 | 2023-06-30 | LOW |
Bellevue Asset Management AG | Investment Advisor | 2.6756 | 2612800 | -500 | 2023-06-30 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 1.9547 | 1908844 | -85677 | 2023-06-30 | LOW |
Armistice Capital LLC | Hedge Fund | 1.6897 | 1650000 | 58000 | 2023-06-30 | MED |
Renaissance Technologies LLC | Hedge Fund | 1.6829 | 1643402 | -303662 | 2023-06-30 | HIGH |
JP Morgan Asset Management | Investment Advisor | 1.6353 | 1596880 | -54369 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.56 | 1523408 | 87671 | 2023-06-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.4331 | 1399439 | 228393 | 2023-06-30 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.3377 | 1306273 | 831881 | 2023-06-30 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 1.3103 | 1279500 | 69400 | 2023-06-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.2666 | 1236839 | -61520 | 2023-06-30 | LOW |
Deerfield Management Company, L.P. | Hedge Fund | 1.2388 | 1209714 | -535000 | 2023-06-30 | MED |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 1.2186 | 1190026 | -30338 | 2023-06-30 | LOW |
Woodline Partners LP | Hedge Fund | 1.1799 | 1152189 | 753495 | 2023-06-30 | HIGH |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.1308 | 1104267 | 242362 | 2023-06-30 | LOW |
Brown Advisory | Investment Advisor/Hedge Fund | 1.1158 | 1089582 | -10274 | 2023-09-30 | LOW |
DSM Capital Partners, LLC | Investment Advisor | 1.0858 | 1060270 | -199261 | 2023-06-30 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.016 | 992153 | -119041 | 2023-06-30 | LOW |
差價合約交易計算器
如果您在特定日期(選取一個日期)開立差價合約交易並在不同日期(選取一個日期)關閉交易,計算您的假設盈虧。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
打開
關閉
做空 做多
Neurocrine Company profile
关于 Neurocrine Biosciences Inc.
Neurocrine Biosciences, Inc.是一家以神经科学为重点的生物制药公司。 公司专注于发现、开发和销售用于治疗神经系统、内分泌和精神疾病和障碍的药物。 其产品组合包括治疗迟发性运动障碍、帕金森病、子宫内膜异位症和子宫肌瘤。 其产品系列包括INGREZZA(缬氨酸),为迟发性运动障碍提供每日一次的治疗选择,有三种剂量选择(40毫克、60毫克和80毫克胶囊);ONGENTYS(阿皮卡朋)是帕金森病患者左旋多巴/卡比多巴的辅助疗法。 ORILISSA (elagolix)用于管理妇女的中度至重度子宫内膜异位症疼痛,ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) 是一种非手术的口服药物选择,用于管理与妇女子宫肌瘤相关的大量月经出血。
Industry: | Bio Therapeutic Drugs |
12780 El Camino Real
SAN DIEGO
CALIFORNIA 92130-2042
US
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗?
加入成为全球570,000万多名交易者的一份子,选择利用Capital.com进行交易吧。